Literature DB >> 8093027

Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194.

K Ohta1, H Hayashi, H Mizuguchi, H Kagamiyama, K Fujimoto, H Fukui.   

Abstract

Based on structural comparison with other biogenic amine receptors and the histamine H2 receptor, it has been suggested that in the human histamine H1 receptor, Asp107, Thr194, and Asn198 are the residues involved in binding of histamine. We therefore used site-directed mutagenesis to investigate the roles of these three amino acid residues. Asp107 was essential for both agonist and antagonist binding. Asn198 was necessary for agonist but not for antagonist binding. Thr194 was not important for either type of binding. A good correlation was found between agonist binding and receptor activation for all the wild-type and mutant receptors. The results show that the histamine H1 receptor recognizes and is activated by histamine through the interactions of Asp107 and the amino group, and Asn198 and the imidazole ring.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8093027     DOI: 10.1006/bbrc.1994.2295

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.

Authors:  Q Jiang; B X Lee; M Glashofer; A M van Rhee; K A Jacobson
Journal:  J Med Chem       Date:  1997-08-01       Impact factor: 7.446

2.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.

Authors:  Chris de Graaf; Albert J Kooistra; Henry F Vischer; Vsevolod Katritch; Martien Kuijer; Mitsunori Shiroishi; So Iwata; Tatsuro Shimamura; Raymond C Stevens; Iwan J P de Esch; Rob Leurs
Journal:  J Med Chem       Date:  2011-11-07       Impact factor: 7.446

3.  Molecular determinants of ligand-directed signaling for the histamine H1 receptor.

Authors:  R G Booth; L Fang; A Wilczynski; S Sivendren; Z Sun; S Travers; M Bruysters; K Sansuk; R Leurs
Journal:  Inflamm Res       Date:  2008       Impact factor: 4.575

4.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

5.  Chemotype-selective modes of action of κ-opioid receptor agonists.

Authors:  Eyal Vardy; Philip D Mosier; Kevin J Frankowski; Huixian Wu; Vsevolod Katritch; Richard B Westkaemper; Jeffrey Aubé; Raymond C Stevens; Bryan L Roth
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

6.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

7.  Functional pharmacology of H1 histamine receptors expressed in mouse preoptic/anterior hypothalamic neurons.

Authors:  I V Tabarean
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

8.  Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.

Authors:  Heidrun Appl; Tobias Holzammer; Stefan Dove; Ekkehard Haen; Andrea Strasser; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-28       Impact factor: 3.000

Review 9.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

10.  Modelling and mutation studies on the histamine H1-receptor agonist binding site reveal different binding modes for H1-agonists: Asp116 (TM3) has a constitutive role in receptor stimulation.

Authors:  A M ter Laak; H Timmerman; R Leurs; P H Nederkoorn; M J Smit; G M Donné-Op den Kelder
Journal:  J Comput Aided Mol Des       Date:  1995-08       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.